PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops non-standard peptide therapeutics addressing unmet medical needs. The company is investigating peptide drug conjugates (PDC), peptides and small molecule-based drugs. PeptiDream pipeline products include PD-L1 - (BMS-986229), CD38 - (BHV-1100 + NK cells), S2-protein (PA-001), GhR (AZP-3813), glypican-3, myostatin, TfR, c-Kit and HA- protein. Its pipeline treats oncology, multiple myeloma, covid-19, acromegaly, liver cancer, muscle disorders, neuromuscular disorders, allergic condition and influenza. PeptiDream is headquartered in Kawasaki, Kanagawa, Japan.
PeptiDream Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline: |
PD-L1 - (BMS-986229) Oncology |
CD38 - ( BHV-1100 + NK Cells) - Multiple Myeloma |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In September, the company entered into an agreement with Genentech for the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates. |
2023 | Contracts/Agreements | In July, the company and Astellas Pharma signed a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. |
2023 | Contracts/Agreements | In March, the company entered into an agreement with Ono Pharmaceutical for the creation and development of a special cyclic peptide drug. |
Competitor Comparison
Key Parameters | PeptiDream Inc | OncoTherapy Science Inc | AnGes Inc | BrightPath Biotherapeutics Co Ltd | Jitsubo Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Kawasaki-Shi | Kawasaki-Shi | Ibaraki-Shi | Chiyoda-Ku | Yokohama |
State/Province | Kanagawa | Kanagawa | Osaka | Tokyo | Kanagawa |
No. of Employees | 603 | 60 | 138 | 32 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Reed Patrick Ph.D | President; Director; Chief Executive Officer | Executive Board | - | - |
Kinjo Scripture Ph.D. | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | - |
Keiichi Masuya Ph.D | Chief Operating Officer; Executive Vice President | Senior Management | - | - |
Masato Murakami Ph.D. | Chief Medical Officer | Senior Management | 2022 | - |
Michio Sasaoka Ph.D. | Director | Non Executive Board | 2012 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer